ALT ‘RECOVERY was designed to provide a robust test of possible treatments for COVID-19 whilst keeping the burden on hospital staff and the health system to a minimum. This approach led to the discovery of effective treatments for COVID-19, such as dexamethasone, which have now saved hundreds of thousands of lives around the world. We are now expanding this approach to tackle the long-term challenge of influenza.’ Professor Sir Martin Landray Professor of Medicine and Epidemiology Joint Chief Investigator of the RECOVERY trial

ALT 'As well as being the greatest pandemic risk, influenza remains a serious annual scourge. In a bad year, as many as 25,000 people in the UK die as a result of influenza. Yet we have no treatments that are proven to improve outcomes in hospitalised influenza patients. By including influenza in the RECOVERY trial, we have the opportunity to change this and find new treatments for this persistent menace.’ Professor Sir Peter Horby Moh Family Foundation Professor of Emerging Infections and Global Health Joint Chief Investigator for the RECOVERY trial